Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• BurdelskiCReiswichVHube-MaggCCytoplasmic accumulation of sequestosome 1 (p62) is a predictor of biochemical recurrence, rapid tumor cell proliferation, and genomic instability in prostate cancerClin Cancer Res201521153471347925925890
   PubMedGoogle Scholar
• BedollaRPrihodaTJKreisbergJIDetermining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activationClin Cancer Res200713133860386717606718
   PubMed Web of Science ®Google Scholar
• ChauxAPeskoeSBGonzalez-RoibonNLoss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancerMod Pathol201225111543154922684219
   PubMed Web of Science ®Google Scholar
• GruppKKohlSSirmaHCysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrenceMod Pathol201326573374223196798
   PubMedGoogle Scholar
• ZhangSYuDPI(3)king apart PTEN’s role in cancerClin Cancer Res201016174325433020622047
   PubMed Web of Science ®Google Scholar
• CourtneyKDCorcoranRBEngelmanJAThe PI3K pathway as drug target in human cancerJ Clin Oncol20102861075108320085938
   PubMed Web of Science ®Google Scholar
• De VelascoMAUemuraHPreclinical remodeling of human prostate cancer through the PTEN/AKT pathwayAdv Urol20122012112
   Google Scholar
• WangXJiangXPTEN: a default gate-keeping tumor suppressor with a versatile tailCell Res200818880781618626510
   PubMedGoogle Scholar
• LinP-CLinJ-KLinH-HA comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancerWorld J Surg Oncol201513118625986931
   PubMedGoogle Scholar
• FerraldeschiRNava RodriguesDRiisnaesRPTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateEur Urol201567479580225454616
   PubMed Web of Science ®Google Scholar
• MithalPAllottEGerberLPTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancerInt J Urol201421121209121425099119
   PubMed Web of Science ®Google Scholar
• MulhollandDJTranLMLiYCell autonomous role of PTEN in regulating castration-resistant prostate cancer growthCancer Cell201119679280421620777
   PubMed Web of Science ®Google Scholar
• KluthMRunteFBarowPConcurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancerInt J Cancer2015137102354236326009879
   PubMed Web of Science ®Google Scholar
• EpsteinJIFengZTrockBJPierorazioPMUpgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary gradesEur Urol20126151019102422336380
   PubMed Web of Science ®Google Scholar
• NohB-JSungJYKimYChangSGParkYKPrognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancerOncol Lett20161163621363027284364
   PubMedGoogle Scholar
• KimSHKimSHJoungJYOverexpression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancerPLoS One2015104e012249825897494
   PubMed Web of Science ®Google Scholar
• PetrovicsGLiHStumpelTA novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American menEBioMedicine20152121957196426844274
   PubMedGoogle Scholar
• LotanTLWeiWMoraisCLPTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancerEur Urol Focus20162218018827617307
   PubMedGoogle Scholar
• QuXJeldresCGlaskovaLIdentification of combinatorial genomic abnormalities associated with prostate cancer early recurrenceJ Mol Diagn201618221522426752304
   PubMed Web of Science ®Google Scholar
• SilvaMPBarros-SilvaJDErsvaerECancer prognosis defined by the combined analysis of 8q, PTEN and ERGTransl Oncol20169657558227916292
   PubMedGoogle Scholar
• McGrathSChristidisDPereraMProstate cancer biomarkers: are we hitting the mark?Prostate Int20164413013527995111
   PubMedGoogle Scholar
• BertoliGCavaCCastiglioniIMicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancerInt J Mol Sci201617342144127011184
   PubMed Web of Science ®Google Scholar
• LuLIZhangHPangJHouGLLuMHGaoXERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancerOncol Lett20161142532253827073512
   PubMedGoogle Scholar
• GiannicoGAArnoldSAGellertLLHameedONew and emerging diagnostic and prognostic immunohistochemical biomarkers in prostate pathologyAdv Anat Pathol20171243544
   Google Scholar
• FilellaXFojLProstate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkersInt J Mol Sci2016171117841805
   PubMedGoogle Scholar
• YoshimotoMCunhaIWCoudryRAFISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBr J Cancer200797567868517700571
   PubMedGoogle Scholar
• AtreyaCESangaleZXuNPTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survivalCancer Med20132449650624156022
   PubMed Web of Science ®Google Scholar
• ZhuXQinXFeiMLoss and reduced expression of PTEN correlate with advanced-stage gastric carcinomaExp Ther Med201351576423251242
   PubMedGoogle Scholar
• TanMHMesterJLNgeowJRybickiLAOrloffMSEngCLifetime cancer risks in individuals with germline PTEN mutationsClin Cancer Res201218240040722252256
   PubMed Web of Science ®Google Scholar
• PriceTJHardinghamJELeeCKPrognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumabCancer Med20132327728523930204
   PubMed Web of Science ®Google Scholar
• TsourlakisMCWeigandPGruppKβIII-tubulin overex-pression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletionAm J Pathol2014184360961724378408
   PubMedGoogle Scholar
• BurdelskiCMenanDTsourlakisMCThe prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionBMC Cancer20151553826202067
   PubMed Web of Science ®Google Scholar